Ligand id: 1133

Name: liraglutide

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Liraglutide is already approved to treat type 2 diabetes and it is in development for the treatment of obesity (Saxenda®) [1].

Recent laboratory research in mice suggests that liraglutide may reduce brain inflammation in Alzheimer's disease (AD), leading to an improvement in the growth of brain cells and the connections between them [3-4]. As a result of this repurposing indication, clinical trials are ongoing to investigate the benefit that use of this drug may bring to the prevention of progression of AD in patients with early signs of the disease. Click here to link to the AD trials involving this drug registered with
Mechanism Of Action and Pharmacodynamic Effects
Liraglutide is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) which acts to
1) upregulate intracellular cAMP resulting in the release of insulin (in the presence of elevated blood glucose) and
2) to decrease glucagon secretion in a glucose-dependent fashion.
External links